LongeVC Backs Interface Biosciences for Advancing Inflammatory Disease Drug Development with AI-Enabled Platform

LongeVC has invested in Interface Biosciences, a company that has recently secured $3 million in seed funding. This investment is a strategic move for LongeVC, reflecting its focus on innovative biotech and longevity startups. Interface Biosciences, specialising in developing pharmaceuticals from bacterial natural products, is advancing towards IND-enabling studies, a critical phase in their development.

Founded by Drs. Hannah C. Wastyk and Will Van Treuren, Interface Biosciences, aims to revolutionise the treatment of inflammatory diseases. Their approach involves discovering and developing drug candidates from a rich yet largely unexplored source of natural products. These candidates have the potential to modulate the immune system and reduce inflammation, offering new avenues for treatment.

LongeVC's investment in Interface Biosciences is part of a broader commitment to support groundbreaking medical research and development. By backing companies like Interface Biosciences, LongeVC is contributing to advancing new medical solutions, particularly in areas where current treatments are insufficient.

For more information, click to read the complete announcement.